Acquisition

Finland's BioNavis takes 64% of Sweden's Attana in reverse acquisition

What's the deal? Sweden's AttanaDealroom has a profile for this one. Try Dealroom → has agreed to acquire all shares in Finnish analytical instruments maker BioNavisDealroom has a profile for this one. Try Dealroom →, combining Attana's QCM biosensor technology with BioNavis's MP-SPR instruments. The consideration is paid entirely in newly issued Attana shares, with BioNavis's owners set to hold about 64% of the combined company — which is why the deal is accounted for as a reverse acquisition.

What's the endgame? The two platforms are complementary, and BioNavis brings an established international distributor network plus roughly 300 instruments sold worldwide since 2011. "Together we create a strong commercial platform with very good conditions to grow and reach profitability faster," said Arne Nabseth, chairman of Attana.

The numbers: BioNavis is profitable, reporting 2025 net sales of US$1.7M and operating profit of US$435.2K, with sales up about 31% on 2024. Attana is the weaker partner: its 2025 sales fell about 40% to US$302.2K and it posted an operating loss of roughly US$1.28M. The deal looks as much a rescue of Attana's commercial scale as a conventional expansion.

Why now? Attana has struggled to raise money — a June 2026 issue drew weak interest — and is now raising about US$544K in a directed share issue to strengthen its liquidity before closing. It also carried out a 1:10,000 share consolidation ahead of the transaction.

The terms: Of the consideration, 80% is paid at closing through about 1.82 million new Attana shares, with the remaining 20% via convertible loans of about US$809.9K.

What could go wrong? The transaction still needs approval at an extraordinary general meeting on December 17 and Swedish foreign direct investment clearance. Closing is expected around December 22.

The signal: A profitable Finnish target absorbing control of a loss-making listed Swedish acquirer shows how reverse acquisitions can give private companies a public listing while handing a struggling parent the commercial scale it couldn't reach alone.

Read more: nordiclifescience.org

Image credit: Generated with Gemini

More top stories